Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
WALTHAM, Mass., Jan. 30, 2012 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody expertise, today announced...
-
Product pipeline progress includes continued advancement of trastuzumab emtansine (T-DM1) toward Phase III data reporting and marketing submission in 2012, initiation of SAR3419 multi-study Phase...
-
WALTHAM, Mass., Jan. 3, 2012 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation...
-
Agreement provides Lilly, a leader in the development of important cancer therapeutics, with access to ImmunoGen's TAP technology ImmunoGen to receive $20 million upfront, milestone payments...
-
WALTHAM, Mass., Dec. 6, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation...
-
WALTHAM, Mass., Nov. 14, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody...
-
WALTHAM, Mass., Nov. 7, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that it has been...
-
WALTHAM, Mass., Nov. 3, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody...
-
WALTHAM, Mass., Nov. 2, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that Company...
-
Lead product candidates have notable developments, while pipeline continues to expand. Recent progress includes positive trastuzumab emtansine (T-DM1) clinical data, advancement of SAR3419...